Penumbra (NYSE:PEN) announced today that it initiated the FORWARD study of its mechanical thrombectomy technology. Alameda, California–based Penumbra's real-world, prospective, multi-center study will collect safety and efficacy data on mechanical thrombectomy. That includes computer-assisted vacuum thrombectomy (CAVT) and modulated aspiration … [Read more...] about Penumbra enrolls first patient in distal acute stroke thrombectomy study
penumbra
Penumbra earns CE mark for Thunderbolt thrombectomy system
Penumbra (NYSE:PEN) announced today that it received CE mark approval for its Thunderbolt thrombectomy system for stroke. European approval for the computer-assisted vacuum thrombectomy (CAVT) technology comes just days after FDA clearance. Thunderbolt expands the company’s computer-assisted vacuum thrombectomy (CAVT) portfolio. It aims to … [Read more...] about Penumbra earns CE mark for Thunderbolt thrombectomy system
Penumbra wins FDA clearance for Thunderbolt computer-assisted vacuum thrombectomy for stroke
Penumbra (NYSE:PEN) announced today that it received FDA clearance for its Thunderbolt thrombectomy platform for stroke. Thunderbolt expands the Alameda, California-based company's computer-assisted vacuum thrombectomy (CAVT) portfolio. It aims to address acute ischemic stroke. Penumbra said Thunderbolt represents a first-of-its-kind … [Read more...] about Penumbra wins FDA clearance for Thunderbolt computer-assisted vacuum thrombectomy for stroke
Study backs Penumbra computer-assisted thrombectomy
Penumbra (NYSE:PEN) today announced 90-day results from the landmark STORM-PE randomized trial of its thrombectomy technology. STORM-PE evaluates patients with acute intermediate-high risk pulmonary embolism (PE) treated with computer-assisted vacuum thrombectomy (CAVT). It utilizes the Alameda, California-based company's Lightning Flash … [Read more...] about Study backs Penumbra computer-assisted thrombectomy
AHA, ACC issue guidelines for pulmonary embolism that affect Boston Scientific, Stryker
New guidelines related to pulmonary embolism could provide a boost for Boston Scientific (NYSE: BSX) and Stryker (NYSE: SYK), among others. Yesterday, the American Heart Association (AHA) and American College of Cardiology (ACC) joint committee updated its guidelines for pulmonary embolism (PE). This marks the first update since the AHA last … [Read more...] about AHA, ACC issue guidelines for pulmonary embolism that affect Boston Scientific, Stryker
Penumbra launches next-gen Lightning Flash 3.0 thrombectomy system
Penumbra (NYSE:PEN) announced today that it launched the Lightning Flash 3.0 computer-assisted vacuum thrombectomy (CAVT) system. The latest-generation Lightning Flash CAVT offering includes significant upgrades, advancing Penumbra's venous thromboembolism (VTE) platform, the company says. Penumbra — which is set to be acquired by Boston … [Read more...] about Penumbra launches next-gen Lightning Flash 3.0 thrombectomy system
Boston Scientific to acquire Penumbra for $14.5B
Boston Scientific (NYSE: BSX) today announced a definitive agreement to acquire cardiovascular disease treatment device maker Penumbra (NYSE:PEN). The deal values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion. Penumbra shares currently trade at approximately $313.43 apiece ahead of the market opening … [Read more...] about Boston Scientific to acquire Penumbra for $14.5B
More data supports Penumbra mechanical thrombectomy system
Penumbra (NYSE:PEN) announced additional results from its STORM-PE trial of computer-assisted vacuum thrombectomy (CAVT). The data release follows STORM-PE findings shared last week supporting the use of the company's Lightning Flash system at TCT 2025. Investigators shared additional results at this week's Vascular Interventional Advances (VIVA) … [Read more...] about More data supports Penumbra mechanical thrombectomy system
Penumbra study backs mechanical thrombectomy for treating pulmonary embolism
Penumbra (NYSE:PEN) today announced positive results from its landmark STORM-PE randomized controlled trial. The study found that the use of the company's computer-assisted vacuum thrombectomy (CAVT) system, a form of mechanical thrombectomy (MT), with anticoagulation achieved superior reduction in right heart strain compared to anticoagulation … [Read more...] about Penumbra study backs mechanical thrombectomy for treating pulmonary embolism
Penumbra promotes from within to fill president position
Penumbra (NYSE:PEN) announced today that it promoted Shruthi Narayan to the position of president of the company. Narayan's appointment goes into effect on Sept. 1, 2025. She continues to report to Adam Elsesser, who previously held the post of president before this promotion. Elsesser continues on as the Penumbra's chair and CEO. The … [Read more...] about Penumbra promotes from within to fill president position
